{"transactions":[{"id":941213,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2026-01-12T22:00:08.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":24687,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6489},"source":{"system":"sec-edgar","filing":"0001193125-26-010575","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526010575/ownership.xml","form_type":"4"}},{"id":941212,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2026-01-12T22:00:08.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13142},"source":{"system":"sec-edgar","filing":"0001193125-26-010575","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526010575/ownership.xml","form_type":"4"}},{"id":941211,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:00:08.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":19631,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc."}],"balance_after":19631,"source":{"system":"sec-edgar","filing":"0001193125-26-010575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526010575/ownership.xml","form_type":"4"}},{"id":1205798,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Shares","published_at":"2025-03-14T20:30:13.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":21179,"price":1.14,"value":24144.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represent shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the vesting and settlement of restricted stock units and does not represent a discretionary sale by the holder."}],"balance_after":124394,"source":{"system":"sec-edgar","filing":"0001415889-25-008105","document":"form4-03142025_040309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588925008105/form4-03142025_040309.xml","form_type":"4"}},{"id":1219722,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-06T22:00:12.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":237000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on March 4, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":237000,"derivative":{"exercise_price":1.17,"expiration_date":"2035-03-03","underlying":"Common Shares","underlying_shares":237000},"source":{"system":"sec-edgar","filing":"0001415889-25-007239","document":"form4-03062025_050306.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588925007239/form4-03062025_050306.xml","form_type":"4"}},{"id":1219721,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Shares","published_at":"2025-03-06T22:00:12.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of March 4, 2026, March 4, 2027 and March 4, 2028, subject to Reporting Person continuing to provide service through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 895 and 2,000 shares acquired on August 15, 2024 and February 15, 2025, respectively, under the Issuer's employee stock purchase plan."}],"balance_after":145573,"source":{"system":"sec-edgar","filing":"0001415889-25-007239","document":"form4-03062025_050306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588925007239/form4-03062025_050306.xml","form_type":"4"}},{"id":1556449,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Shares","published_at":"2024-04-02T01:31:38.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":2491,"price":4.63,"value":11533.33,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.58 to $4.65 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":107558,"source":{"system":"sec-edgar","filing":"0001415889-24-009629","document":"form4-04022024_010432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588924009629/form4-04022024_010432.xml","form_type":"4"}},{"id":1556448,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Shares","published_at":"2024-04-02T01:31:38.000Z","date":"2024-03-28","kind":"sale","planned":true,"acquired":false,"shares":2650,"price":4.62,"value":12243.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The change in the total shares prior to the transactions reported herein reflects a change in form of ownership from direct to indirect, which was exempt from reporting pursuant to Rule 16a-13."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":110049,"source":{"system":"sec-edgar","filing":"0001415889-24-009629","document":"form4-04022024_010432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588924009629/form4-04022024_010432.xml","form_type":"4"}},{"id":1559573,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Shares","published_at":"2024-03-27T22:54:49.000Z","date":"2024-03-27","kind":"sale","planned":true,"acquired":false,"shares":2650,"price":4.63,"value":12269.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.77 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":83866,"source":{"system":"sec-edgar","filing":"0001415889-24-009249","document":"form4-03272024_100342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588924009249/form4-03272024_100342.xml","form_type":"4"}},{"id":1559572,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Shares","published_at":"2024-03-27T22:54:49.000Z","date":"2024-03-26","kind":"sale","planned":true,"acquired":false,"shares":2650,"price":4.64,"value":12296.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.83 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":86516,"source":{"system":"sec-edgar","filing":"0001415889-24-009249","document":"form4-03272024_100342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588924009249/form4-03272024_100342.xml","form_type":"4"}},{"id":1559571,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Shares","published_at":"2024-03-27T22:54:49.000Z","date":"2024-03-25","kind":"sale","planned":true,"acquired":false,"shares":2650,"price":4.79,"value":12693.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":89166,"source":{"system":"sec-edgar","filing":"0001415889-24-009249","document":"form4-03272024_100342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588924009249/form4-03272024_100342.xml","form_type":"4"}},{"id":1603426,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-05T02:04:42.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":237000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on March 1, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":237000,"derivative":{"exercise_price":6.95,"expiration_date":"2034-02-28","underlying":"Common Shares","underlying_shares":237000},"source":{"system":"sec-edgar","filing":"0001415889-24-006464","document":"form4-03052024_020338.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588924006464/form4-03052024_020338.xml","form_type":"4"}},{"id":1603425,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Shares","published_at":"2024-03-05T02:04:42.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of March 1, 2025, March 1, 2026 and March 1, 2027, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":124677,"source":{"system":"sec-edgar","filing":"0001415889-24-006464","document":"form4-03052024_020338.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000141588924006464/form4-03052024_020338.xml","form_type":"4"}},{"id":2038630,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-02T02:44:37.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":344200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on January 30, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":344200,"derivative":{"exercise_price":12.42,"expiration_date":"2033-01-29","underlying":"Common Shares","underlying_shares":344200},"source":{"system":"sec-edgar","filing":"0001209191-23-006062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919123006062/doc4.xml","form_type":"4"}},{"id":2038629,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2023-02-02T02:44:37.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":78550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of January 30, 2024, January 30, 2025 and January 30, 2026, subject to Reporting Person continuing to provide service through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 398 shares and 729 shares acquired on August 13, 2021 and February 15, 2022, respectively, under the Issuer's employee stock purchase plan."}],"balance_after":84677,"source":{"system":"sec-edgar","filing":"0001209191-23-006062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919123006062/doc4.xml","form_type":"4"}},{"id":2427860,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-24T21:55:15.000Z","date":"2022-01-21","kind":"exercise","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This Form 4 amendment is being filed to correct the original Form 4 filed on January 20, 2022. The original Form 4 was filed early with an incorrect Transaction Date due to a clerical error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on January 18, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":300000,"derivative":{"exercise_price":15.63,"expiration_date":"2032-01-20","underlying":"Common Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-22-004623","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919122004623/doc4a.xml","form_type":"4/A","original_submission_date":"2022-01-20"}},{"id":2430714,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-20T21:40:59.000Z","date":"2022-01-18","kind":"exercise","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on January 18, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":300000,"derivative":{"exercise_price":15.63,"expiration_date":"2032-01-17","underlying":"Common Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-22-004045","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919122004045/doc4.xml","form_type":"4"}},{"id":2650363,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-06-30T21:54:48.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":1542,"price":35.61,"value":54910.62,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":94466,"source":{"system":"sec-edgar","filing":"0001209191-21-044032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121044032/doc4.xml","form_type":"4"}},{"id":2674124,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-06-10T22:35:05.000Z","date":"2021-06-09","kind":"sale","acquired":false,"shares":1576,"price":35,"value":55160.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":96008,"source":{"system":"sec-edgar","filing":"0001209191-21-039621","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121039621/doc4.xml","form_type":"4"}},{"id":2679505,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-06-07T22:36:22.000Z","date":"2021-06-04","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-five percent (25%) of the shares subject to the option vested on June 22, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":283683,"derivative":{"exercise_price":1.637,"expiration_date":"2027-06-22","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-038747","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121038747/doc4.xml","form_type":"4"}},{"id":2679504,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-06-07T22:36:22.000Z","date":"2021-06-04","kind":"sale","acquired":false,"shares":5000,"price":31.25,"value":156250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.49 inclusive."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-21-038747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121038747/doc4.xml","form_type":"4"}},{"id":2679503,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-06-07T22:36:22.000Z","date":"2021-06-04","kind":"exercise","acquired":true,"shares":5000,"price":1.637,"value":8185.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-21-038747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121038747/doc4.xml","form_type":"4"}},{"id":2679502,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-06-07T22:36:22.000Z","date":"2021-06-04","kind":"sale","acquired":false,"shares":12172,"price":31.36,"value":381713.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.215 to $31.65 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":97584,"source":{"system":"sec-edgar","filing":"0001209191-21-038747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121038747/doc4.xml","form_type":"4"}},{"id":2679501,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-06-07T22:36:22.000Z","date":"2021-06-04","kind":"sale","acquired":false,"shares":17180,"price":30.64,"value":526395.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.19 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":109756,"source":{"system":"sec-edgar","filing":"0001209191-21-038747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121038747/doc4.xml","form_type":"4"}},{"id":2679500,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-06-07T22:36:22.000Z","date":"2021-06-03","kind":"sale","acquired":false,"shares":6648,"price":31.74,"value":211007.52,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to\n$32.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":126936,"source":{"system":"sec-edgar","filing":"0001209191-21-038747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121038747/doc4.xml","form_type":"4"}},{"id":2701036,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-05-21T20:02:36.000Z","date":"2021-05-20","kind":"sale","acquired":false,"shares":3770,"price":35.0306,"value":132065.362,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":133584,"source":{"system":"sec-edgar","filing":"0001209191-21-034874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121034874/doc4.xml","form_type":"4"}},{"id":2703438,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-05-20T22:19:00.000Z","date":"2021-05-19","kind":"sale","acquired":false,"shares":3800,"price":35.06,"value":133228.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.25, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":137354,"source":{"system":"sec-edgar","filing":"0001209191-21-034571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121034571/doc4.xml","form_type":"4"}},{"id":2703437,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-05-20T22:19:00.000Z","date":"2021-05-18","kind":"sale","acquired":false,"shares":1800,"price":35,"value":63000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":141154,"source":{"system":"sec-edgar","filing":"0001209191-21-034571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121034571/doc4.xml","form_type":"4"}},{"id":2745303,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-19T21:44:07.000Z","date":"2021-04-15","kind":"sale","acquired":false,"shares":5512,"price":35.01,"value":192975.12,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the \"Company\"). The Reporting Person is the sole stockholder of the Company."}],"balance_after":142954,"source":{"system":"sec-edgar","filing":"0001209191-21-027344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121027344/doc4.xml","form_type":"4"}},{"id":2869492,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-11T02:04:58.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on February 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":125000,"derivative":{"exercise_price":36.91,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-21-009487","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919121009487/doc4.xml","form_type":"4"}},{"id":3099920,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-25T22:00:06.000Z","date":"2020-06-23","kind":"purchase","acquired":true,"shares":5000,"price":20,"value":100000.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-20-038975","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919120038975/doc4.xml","form_type":"4"}},{"id":3104464,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":69538,"kind":"person","name":"Segal Lloyd Mitchell","position":1,"cik":"0001477123","reported_name":"Segal Lloyd Mitchell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-06-19T12:07:57.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":354668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on June 18, 2021, and one thirty-sixth (1/36th) of the remaining shares\nsubject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such\ndate."}],"balance_after":354668,"derivative":{"exercise_price":20,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":354668},"source":{"system":"sec-edgar","filing":"0001209191-20-037782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000120919120037782/doc4.xml","form_type":"4"}}]}